A bidding conflict has damaged into the open for obesity-focused Metsera, with Novo Nordisk on Thursday saying it had made a suggestion for the biotech, a month after Pfizer introduced its plan to buy the agency.
The Novo supply, what it referred to as “an unsolicited proposal,” displays the strain pharma corporations are underneath to realize an edge within the white-hot weight problems market. It additionally appears to have gained traction with Metsera.
After Novo introduced its transfer, which Pfizer referred to as “reckless and unprecedented,” Metsera issued an announcement saying it thought-about the Danish agency’s supply “superior” and delivered a discover to Pfizer saying as a lot. Below the phrases of its settlement with Pfizer, Metsera mentioned, that discover now means Pfizer has 4 enterprise days to renegotiate the phrases of its supply.
This text is unique to STAT+ subscribers
Unlock this text — plus every day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.